NASDAQ:COCH

Envoy Medical Q2 2024 Earnings Report

Envoy Medical logo
$0.65 -0.01 (-1.54%)
As of 06/23/2026 04:00 PM Eastern

Envoy Medical EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Envoy Medical Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
$0.08 million
Beat/Miss
Missed by -$10.00 thousand
YoY Revenue Growth
N/A

Envoy Medical Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Monday, August 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Envoy Medical's Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules

Envoy Medical Earnings Headlines

This Startup is Growing 23X Faster than Nvidia
Former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before gains as high as 52,400%, 2,150%, and 36,000% - is now pointing to an Elon Musk-backed startup growing 23 times faster than Nvidia. The Atlantic called it 'the fastest-growing business in the history of capitalism.' Brown says everyday investors can claim a pre-IPO stake for less than $50, ahead of what he believes could be Wall Street's next major IPO.tc pixel
Envoy Medical Inc - Ordinary Shares - Class A
See More Envoy Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals. The company works closely with healthcare providers to integrate its device into patient care pathways, supporting therapy both in clinical environments and at home.

Headquartered in the Minneapolis–Saint Paul metropolitan area, Envoy Medical currently serves the U.S. market and is evaluating opportunities for expansion into select international regions. Its leadership team combines expertise in medical device development, rehabilitation sciences and commercial operations, backed by private financing aimed at advancing innovative therapies for neurological and musculoskeletal disorders.

View Envoy Medical Profile